DGAP-News: Competitive Technologies to Exhibit Calmare(R) Pain Therapy Device at American Society of Clinical Oncology Annual Meeting June 3-7, 2011

Competitive Technologies, Inc.

02.06.2011 18:24
—————————————————————————

FAIRFIELD, Conn., 2011-06-02 18:24 CEST (GLOBE NEWSWIRE) —
Competitive Technologies, Inc. (OTCQX:CTTC) announced today that its Calmare(r)
pain therapy medical device featuring Scrambler Therapy? technology will be
exhibited at the American Society of Clinical Oncology (ASCO) Annual Meeting
held at McCormick Place in Chicago, Illinois June 3-7, 2011. At the meeting,
company representatives will showcase the Calmare device that clinical trials
have shown to be effective in treating pain caused by cancer, especially
chemotherapy induced peripheral neuropathy or CIPN.

The Calmare team at Booth 2104 with the device will consist of Tim Conley,
Calmare National Sales Manager; Frank Sparadeo, Ph.D., researcher and
collaborator at Calmar Pain Relief; Jerry Stringham, President of Medical
Technology Partners, reimbursement consultant; and Aris Despo, CTTC–s Executive
Vice President. View www.calmarett.com.

–We are looking forward to sharing the Calmare device–s clinical success in
treating CIPN with doctors who are on the frontline in the battle against
CIPN,– said Mr. Despo. –While these medical professionals are treating cancer,
they are also concerned about the negative side effects of the treatments they
use to fight the spread of cancer. Our device offers them an effective
treatment option without side effects to help their patients suffering from
CIPN.

–We have seen a significant increase in interest in our non-invasive, drug-free
therapy following the publication in December 2010 of results from the study
completed by Dr. Thomas Smith, M.D. and others from the VCU Massey Cancer
Center. Additional studies of the Calmare device–s efficacy in treating CIPN,
cancer-related pain and other types of neuropathic pain are underway at VCU
Massey, as well as the University of Wisconsin, Madison and at the Mayo
Clinic.–

About Competitive Technologies, Inc

Competitive Technologies is a global leader in developing and commercializing
innovative products and technologies. CTTC is multifaceted, providing
distribution, patent and technology transfer, sales and licensing services.
CTTC–s staff is focused on the needs of customers and matching those
requirements with commercially viable products or technology solutions.
Competitive Technologies was established in 1968.

CTTC is the licensed worldwide distributor of the non-invasive Calmare(r) pain
therapy medical device, which incorporates the biophysical Scrambler Therapy?
technology developed in Italy by CTTC–s client, Professor Giuseppe Marineo to
treat neuropathic pain, including cancer pain. The Calmare device is currently
being manufactured for sale by CTTC–s partner, GEOMC Co., Ltd. of Seoul, Korea.
For more information on the device, visit www.calmarett.com. Visit CTTC–s
website: www.competitivetech.net.

Statements made about our future expectations are forward-looking statements
and subject to risks and uncertainties as described in our most recent Annual
Report on Form 10-K for the year ended July 31, 2010, filed with the SEC on
October 27, 2010, and other filings with the SEC, and are subject to change at
any time. Our actual results could differ materially from these forward-looking
statements. We undertake no obligation to update publicly any forward-looking
statement.

Jean Wilczynski, IR Services, LLC
(860.434.2465 / info@corpirservices.com)
News Source: NASDAQ OMX

02.06.2011 Dissemination of a Corporate News, transmitted by DGAP –
a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.

DGAP–s Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

—————————————————————————

Language: English
Company: Competitive Technologies, Inc.

United States
Phone:
Fax:
E-mail:
Internet:
ISIN: US2045121074
WKN:

End of Announcement DGAP News-Service

—————————————————————————